Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT‐1 trial

医学 析因分析 超重 2型糖尿病 肥胖 糖尿病 内科学 内分泌学
作者
Emily R. Hankosky,Hui Wang,Lisa M. Neff,Hong Kan,Fangyu Wang,Nadia N. Ahmad,Adam Stefański,W. Timothy Garvey
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:25 (12): 3748-3756 被引量:16
标识
DOI:10.1111/dom.15269
摘要

Abstract Aim We assessed the impact of tirzepatide on 10‐year predicted risk of developing type 2 diabetes (T2D) among participants in the SURMOUNT‐1 trial. Materials and Methods In this post hoc analysis of SURMOUNT‐1, the Cardiometabolic Disease Staging risk engine was used to calculate the 10‐year predicted risk of T2D at baseline, week 24 and week 72 among participants randomized to receive 5, 10, or 15 mg tirzepatide or placebo. Mean changes in risk scores from baseline to weeks 24 and 72 were compared between tirzepatide and placebo groups. Subgroup analyses were conducted based on participants' glycaemic status and body mass index at baseline. Results Mean baseline T2D predicted risk scores did not differ between tirzepatide and placebo groups (range: 22.9%‐24.3%). At week 72, mean absolute T2D predicted risk score reductions were significantly greater in tirzepatide groups (5 mg, 12.4%; 10 mg, 14.4%; 15 mg, 14.7%) versus placebo (0.7%). At week 72, median relative predicted risk reductions following tirzepatide treatment ranged from 60.3% to 69.0%. For participants with and without prediabetes, risk reductions were significantly greater in tirzepatide groups versus placebo. At week 72, participants with prediabetes (range: 16.0%‐20.3%) had greater mean risk score reductions from baseline versus those without prediabetes (range: 10.1%‐11.3%). Across body mass index subgroups, mean reductions from baseline were significantly greater in tirzepatide groups versus placebo. Conclusion Tirzepatide treatment significantly reduced the 10‐year predicted risk of developing T2D compared with placebo in participants with obesity or overweight, regardless of baseline glycaemic status.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
1秒前
1秒前
1秒前
2秒前
光_sun完成签到,获得积分10
2秒前
腦內小劇場完成签到,获得积分10
2秒前
无花果应助徐xmr采纳,获得10
2秒前
2秒前
木木酱完成签到,获得积分10
3秒前
yuajianhei完成签到,获得积分10
3秒前
CNAxiaozhu7完成签到,获得积分10
3秒前
莫三颜发布了新的文献求助10
3秒前
3秒前
敢甘完成签到,获得积分10
3秒前
qqj发布了新的文献求助80
4秒前
DD发布了新的文献求助10
4秒前
微笑完成签到,获得积分10
5秒前
real_cy完成签到,获得积分10
5秒前
5秒前
5秒前
星星轨迹完成签到,获得积分10
5秒前
popooo完成签到,获得积分10
6秒前
7秒前
风清扬发布了新的文献求助10
7秒前
Ava应助yangjiang采纳,获得10
7秒前
桃花落完成签到,获得积分10
7秒前
研友_VZG7GZ应助darmy采纳,获得10
7秒前
9秒前
9秒前
zhaoyuyuan发布了新的文献求助10
9秒前
9秒前
9秒前
汉堡包应助shuangcheng采纳,获得10
10秒前
清脆靳完成签到,获得积分10
11秒前
11秒前
充电宝应助故意的灯泡采纳,获得10
11秒前
8R60d8应助readhistory采纳,获得10
11秒前
esbd完成签到,获得积分10
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969060
求助须知:如何正确求助?哪些是违规求助? 3513962
关于积分的说明 11171223
捐赠科研通 3249302
什么是DOI,文献DOI怎么找? 1794772
邀请新用户注册赠送积分活动 875377
科研通“疑难数据库(出版商)”最低求助积分说明 804769